Spots Global Cancer Trial Database for neuroblastoma
Every month we try and update this database with for neuroblastoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan | NCT02030964 | Neuroblastoma | DFMO Celecoxib Cyclophosphamid... Topotecan | 2 Years - 30 Years | New Approaches to Neuroblastoma Therapy Consortium | |
| Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma | NCT02075177 | Recurrent Neuro... Neuroblastoma | Fenretinide Lym... Ketoconazole | - | South Plains Oncology Consortium | |
| Combination Chemotherapy or Observation Following Surgery in Treating Infants With Neuroblastoma | NCT00002803 | Neuroblastoma | cyclophosphamid... doxorubicin hyd... vincristine sul... conventional su... | - 1 Year | National Cancer Institute (NCI) | |
| Biomarkers in Samples From Young Patients With Neuroblastoma | NCT01358604 | Neuroblastoma | polymerase chai... protein express... western blottin... flow cytometry immunohistochem... laboratory biom... | - 120 Years | Children's Oncology Group | |
| Combination Chemotherapy in Treating Children With Neuroblastoma | NCT00003093 | Neuroblastoma | filgrastim sargramostim carboplatin cyclophosphamid... doxorubicin hyd... etoposide conventional su... neoadjuvant the... | - 20 Years | Children's Oncology Group | |
| Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma | NCT02298348 | Neuroblastoma | Sorafenib Cyclophosphamid... Topotecan | - 30 Years | New Approaches to Neuroblastoma Therapy Consortium | |
| Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma | NCT00450827 | Neuroblastoma | bevacizumab filgrastim autologous hema... iodine I 131 mo... | 1 Year - | Memorial Sloan Kettering Cancer Center | |
| Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9 | NCT00582608 | CNS Cancer Neuroblastoma Sarcoma | 131I-8H9 8H9 | 1 Year - 50 Years | Memorial Sloan Kettering Cancer Center | |
| N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma | NCT00659984 | Neuroblastoma | UltratraceTM Io... UltratraceTM Io... | 1 Year - 30 Years | Molecular Insight Pharmaceuticals, Inc. | |
| New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma | NCT00001335 | Ewing's Sarcoma Neuroblastoma Rhabdomyosarcom... | ADR-529 Topotecan G-CSF | - | National Institutes of Health Clinical Center (CC) | |
| Reduced Intensity Stem Cell Transplantation in Children With Relapsed Neuroblastoma After Autologous Transplantation | NCT00793351 | Neuroblastoma | Reduced-intensi... | - 20 Years | Samsung Medical Center | |
| Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma | NCT00202930 | Neuroblastoma Opsoclonus-myoc... | anti-CD20 (Ritu... | 2 Months - 18 Years | University of Pittsburgh | |
| Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features | NCT01048892 | Adrenocortical ... Gastrointestina... Kidney Cancer Neuroblastoma Retinoblastoma Sarcoma | Seneca Valley v... cyclophosphamid... laboratory biom... pharmacological... | 3 Years - 21 Years | Children's Oncology Group | |
| Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib | NCT04753658 | Neuroblastoma | lorlatinib | 0 Years - | Pfizer | |
| Combination Chemotherapy Before Surgery in Treating Children With Localized Neuroblastoma | NCT00025428 | Neuroblastoma | carboplatin cyclophosphamid... doxorubicin hyd... etoposide vincristine sul... adjuvant therap... conventional su... neoadjuvant the... | 1 Year - 18 Years | National Cancer Institute (NCI) | |
| A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells | NCT00703222 | Neuroblastoma | SNJB-JF-IL2 and... SNJB-JF-IL2 and... | - | Baylor College of Medicine | |
| Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers | NCT03860207 | Neuroblastoma Osteosarcoma Other Solid Tum... | Humanized 3F8 B... Blood draw | 1 Year - 17 Years | Y-mAbs Therapeutics | |
| ODSH + ICE Chemotherapy in Pediatric Solid Tumors | NCT02164097 | Recurrent Solid... Refractory Soli... Sarcoma Wilms' Tumor Neuroblastoma | ODSH | 1 Year - 21 Years | New York Medical College | |
| Understanding Patient Perspectives on the Risks of Ionizing Radiation Used for Medical Imaging | NCT01482741 | Breast Cancer Colon Cancer Lung Cancer Neuroblastoma Testicular Canc... | Focus Group Ses... Focus Group Ses... Focus Group Ses... Focus Group Ses... Focus Group Ses... Focus Group Ses... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | NCT04337177 | Solid Tumors Neuroblastoma Rhabdomyosarcom... Ewing Sarcoma Hepatoblastoma Medulloblastoma | VAL-413 Temozolomide | 1 Year - 30 Years | Valent Technologies, LLC | |
| Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma. | NCT00025597 | Neuroblastoma | carboplatin cyclophosphamid... doxorubicin hyd... etoposide vincristine sul... conventional su... | - 1 Year | National Cancer Institute (NCI) | |
| Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma | NCT00006102 | Brain and Centr... Lymphoma Neuroblastoma Retinoblastoma Sarcoma Unspecified Chi... | becatecarin | - 21 Years | National Cancer Institute (NCI) | |
| A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | NCT01125800 | Medulloblastoma Rhabdomyosarcom... Neuroblastoma Hepatoblastoma Glioma Astrocytoma | LDE225 | 12 Months - 18 Years | Novartis | |
| Aflac ST1001 Prolonged Isotretinoin | NCT01319838 | Neuroblastoma | Isotretinoin | - 30 Years | Emory University | |
| Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma | NCT00539500 | Neuroblastoma | Carboplatin Etoposide Melphalan Stem Cell Infus... ClinicMACS | - | M.D. Anderson Cancer Center | |
| 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma | NCT01183429 | Neuroblastoma | 3F8 and 13-cis-... | 18 Months - | Memorial Sloan Kettering Cancer Center | |
| Expanded Access Protocol Using 131I-MIBG | NCT01590680 | Neuroblastoma Pheochromocytom... Paraganglioma | I-131 MIBG | 12 Months - | Jubilant DraxImage Inc. | |
| Determining Patterns In Study Experiences of Neuroblastoma Patients | NCT05918432 | Neuroblastoma | 18 Years - | Power Life Sciences Inc. | ||
| hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma | NCT00082758 | Neuroblastoma | hu14.18-Interle... | - 21 Years | Children's Oncology Group | |
| Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features | NCT00314925 | Carcinoid Neuroendocrine | Seneca Valley V... | 18 Years - | Neotropix | |
| Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors | NCT02390843 | Retinoblastoma Clear Cell Sarc... Renal Cell Carc... Rhabdoid Tumor Wilms Tumor Hepatoblastoma Neuroblastoma Germ Cell Tumor... Ewings Sarcoma Non-rhabdomyosa... Osteosarcoma Rhabdomyosarcom... | Simvastatin Cyclophosphamid... Topotecan Myeloid growth ... | 1 Year - 29 Years | Emory University | |
| TEMOkids Study : A Phase I Pediatric Study for KIMOZO, Oral Suspension of Temozolomide | NCT04610736 | Pediatric Cance... | Temozolomide Or... | 1 Year - 17 Years | Orphelia Pharma | |
| Interleukin-2 in Treating Children With Stage IV Neuroblastoma Who Have Received Induction Therapy and Peripheral Stem Cell Transplantation | NCT00003743 | Neuroblastoma | aldesleukin | 1 Year - 21 Years | National Cancer Institute (NCI) | |
| Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma | NCT03478462 | Pediatric Solid... Pediatric Lymph... Pediatric Brain... DIPG Neuroblastoma Ewing Sarcoma Rhabdomyosarcom... Osteosarcoma | CLR 131 | 2 Years - 25 Years | Cellectar Biosciences, Inc. | |
| Genetic Susceptibility Biomarkers in Children With Neuroblastoma (Also Known as Neuroblastoma Epidemiology in North America [NENA]) | NCT01119560 | Neuroblastoma | Cytology Specim... Laboratory Biom... Questionnaire A... | - | Children's Oncology Group | |
| HGS-ETR2 to Treat Children With Solid Tumors | NCT00428272 | Ewing's Sarcoma Osteosarcoma Neuroblastoma Rhabdomyosarcom... | Lexatumumab alo... Lexatumumab in ... Interferon gamm... Gamma 1b potent... | 1 Year - 30 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients | NCT00969722 | Primary Refract... | MAb-3F8 Subcutaneous Gr... 13-cis-Retinoic... | 18 Months - 13 Years | United Therapeutics | |
| Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma | NCT00410631 | Neuroblastoma | filgrastim carboplatin cisplatin cyclophosphamid... dacarbazine doxorubicin hyd... etoposide phosp... ifosfamide isotretinoin melphalan topotecan hydro... vincristine sul... vindesine autologous hema... conventional su... peripheral bloo... iobenguane I 13... radiation thera... | - 21 Years | National Cancer Institute (NCI) | |
| Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma | NCT00037011 | Neuroblastoma | beta-glucan monoclonal anti... | - 49 Years | Memorial Sloan Kettering Cancer Center | |
| Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma | NCT01460901 | Neuroblastoma | GD2 CAR modifie... | 18 Months - 17 Years | Children's Mercy Hospital Kansas City | |
| NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors | NCT01875601 | Solid Tumors Brain Tumors Sarcoma Pediatric Cance... Neuroblastoma | Recombinant hum... NK Cell Infusio... | 2 Years - 29 Years | National Institutes of Health Clinical Center (CC) | |
| Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors | NCT00003203 | Brain Tumors Central Nervous... Neuroblastoma | filgrastim carboplatin cisplatin cyclophosphamid... vincristine sul... adjuvant therap... radiation thera... | 3 Years - 21 Years | Children's Oncology Group | |
| Eligibility Screening for a NCI Pediatric Oncology Branch Research Study | NCT00026780 | Ewing Sarcoma Osteosarcoma Neuroblastoma Acute Lymphobla... Neurofibromatos... | - 35 Years | National Institutes of Health Clinical Center (CC) | ||
| Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors | NCT01662804 | Neuroblastoma | 3F8 Monoclonal ... | 13 Months - | Memorial Sloan Kettering Cancer Center | |
| 131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma | NCT00293319 | Neuroblastoma | filgrastim iobenguane I 13... | 1 Year - | University of California, San Francisco | |
| A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | NCT00947167 | Neuroendocrine ... Carcinoid Tumor... Adrenal Gland T... Neuroblastoma Pancreatic Neur... Multiple Endocr... | pertuzumab erlotinib | - | Stanford University | |
| The Role of Glycosyltransferases in the Oncogenesis of Neuroblastoma | NCT01058798 | Neuroblastoma | - 18 Years | National Taiwan University Hospital | ||
| A Vaccine Study for High Risk Cancers | NCT00944580 | Neuroblastoma Rhabdomyosarcom... Osteogenic Sarc... | MAGE-A1, MAGE-A... | 1 Year - 70 Years | Penn State University | |
| A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma | NCT03033303 | Neuroblastoma | Hu3F8 GM-CSF Isotretinoin | - | Memorial Sloan Kettering Cancer Center | |
| Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma | NCT00017225 | Neuroblastoma | filgrastim carboplatin cisplatin cyclophosphamid... dacarbazine doxorubicin hyd... etoposide ifosfamide melphalan tretinoin vincristine sul... vindesine autologous bone... conventional su... peripheral bloo... radiation thera... | - 20 Years | National Cancer Institute (NCI) | |
| A Study of N9 Chemotherapy in Children With Neuroblastoma | NCT04947501 | Neuroblastoma Pediatric Cance... | Cyclophosphamid... Topotecan Vincristine Doxorubicin Ifosfamide Etoposide Carboplatin Mesna | 1 Year - 19 Years | Memorial Sloan Kettering Cancer Center | |
| Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors | NCT03373097 | Neuroblastoma Neuroblastoma R... GD2-positive So... Osteosarcoma Ewing Sarcoma Sarcoma | GD2-CART01 | 12 Months - 25 Years | Bambino Gesù Hospital and Research Institute | |
| Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer | NCT00003661 | Graft Versus Ho... Leukemia Lymphoma Myelodysplastic... Neuroblastoma | anti-thymocyte ... busulfan cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera... | - 54 Years | Roswell Park Cancer Institute | |
| DNA Vaccination Against Neuroblastoma | NCT04049864 | Relapsed Neurob... | DNA vaccine Salmonella oral... Lenalidomide | 1 Year - 20 Years | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology | |
| 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma | NCT04903899 | Neuroblastoma R... Neuroblastoma | 177Lu-DOTATATE | 18 Months - 18 Years | Karolinska University Hospital | |
| Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma | NCT00992173 | Neuroblastoma | Ultratrace Iobe... | 12 Months - | Molecular Insight Pharmaceuticals, Inc. | |
| Expanded Access Protocol Using 131I-MIBG | NCT01590680 | Neuroblastoma Pheochromocytom... Paraganglioma | I-131 MIBG | 12 Months - | Jubilant DraxImage Inc. | |
| A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Children With Cancer | NCT00754286 | Brain Tumors Leukemia Sarcomas Neuroblastoma Lymphoma Hodgkins Diseas... | Aromatherapy Sc... Placebo wand | 7 Years - 21 Years | Albert Einstein College of Medicine | |
| A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | NCT00947167 | Neuroendocrine ... Carcinoid Tumor... Adrenal Gland T... Neuroblastoma Pancreatic Neur... Multiple Endocr... | pertuzumab erlotinib | - | Stanford University | |
| Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma | NCT00004188 | Neuroblastoma | filgrastim carboplatin cisplatin cyclophosphamid... doxorubicin hyd... etoposide isotretinoin melphalan topotecan hydro... vincristine sul... autologous bone... bone marrow abl... conventional su... peripheral bloo... radiation thera... | - 30 Years | Children's Oncology Group | |
| SIOPEN BIOPORTAL, An International Registry Linked to a Virtual Biobank for Patients With Peripheral Neuroblastic Tumours | NCT05192980 | Neuroblastoma Ganglioneurobla... Ganglioneuroma | No Intervention... | - | Institut Curie | |
| A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma | NCT04936529 | Neuroblastoma | β-glucan GM-CSF OPT-821 | - | Memorial Sloan Kettering Cancer Center | |
| 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma | NCT01183429 | Neuroblastoma | 3F8 and 13-cis-... | 18 Months - | Memorial Sloan Kettering Cancer Center | |
| Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma | NCT01387724 | Neuroblastoma | RNA analysis polymerase chai... protein express... proteomic profi... western blottin... enzyme-linked i... immunohistochem... laboratory biom... liquid chromato... mass spectromet... | 1 Year - 10 Years | Children's Oncology Group | |
| Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors | NCT00003461 | Brain and Centr... Metastatic Canc... Neuroblastoma | surgical proced... astatine At 211... | 18 Years - | Duke University | |
| Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma | NCT01838187 | Neuroblastoma Pheochromocytom... Paraganglioma | I-131 MIBG Vorinostat | 12 Months - | Children's Hospital Medical Center, Cincinnati | |
| A Study of N9 Chemotherapy in Children With Neuroblastoma | NCT04947501 | Neuroblastoma Pediatric Cance... | Cyclophosphamid... Topotecan Vincristine Doxorubicin Ifosfamide Etoposide Carboplatin Mesna | 1 Year - 19 Years | Memorial Sloan Kettering Cancer Center | |
| I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma | NCT00590096 | Neuroblastoma Pheochromocytom... | 2 Weeks - | Children's Hospital Medical Center, Cincinnati | ||
| A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors | NCT02536183 | Pediatric Cance... Solid Tumors Rhabdomyosarcom... Ewing Sarcoma Soft Tissue Sar... Osteosarcoma Neuroblastoma Wilms Tumor Hepatic Tumor Germ Cell Tumor... | Magnetic resona... Lyso-thermosens... | - 30 Years | Children's National Research Institute | |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors | NCT04029688 | Acute Myeloid L... Acute Lymphobla... Neuroblastoma Solid Tumors | Idasanutlin Venetoclax Cyclophosphamid... Topotecan Fludarabine Cytarabine Intrathecal Che... | 0 Years - 30 Years | Hoffmann-La Roche | |
| N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma | NCT00093353 | Diarrhea Drug/Agent Toxi... Neuroblastoma | cefixime irinotecan hydr... temozolomide | 1 Year - 30 Years | Children's Hospital Los Angeles | |
| Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors | NCT02013336 | Recurrent or Re... Ewing Sarcoma Rhabdomyosarcom... Neuroblastoma Osteosarcoma | MM-398 (Irinote... | 12 Months - 20 Years | South Plains Oncology Consortium | |
| Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer | NCT00357500 | Central Nervous... Leukemia Lymphoma Neuroblastoma Sarcoma Unspecified Chi... | celecoxib cyclophosphamid... etoposide fenofibrate thalidomide | - 21 Years | Dana-Farber Cancer Institute | |
| Understanding Patient Perspectives on the Risks of Ionizing Radiation Used for Medical Imaging | NCT01482741 | Breast Cancer Colon Cancer Lung Cancer Neuroblastoma Testicular Canc... | Focus Group Ses... Focus Group Ses... Focus Group Ses... Focus Group Ses... Focus Group Ses... Focus Group Ses... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Pediatric Solid Tumor Metabolism [A Prospective Study Exploring Metabolism of Solid Tumors in Pediatrics] | NCT03686566 | Neuroblastoma Sarcoma Pediatric Cance... | 13C-glucose No glucose infu... | - 26 Years | University of Texas Southwestern Medical Center | |
| A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma | NCT04936529 | Neuroblastoma | β-glucan GM-CSF OPT-821 | - | Memorial Sloan Kettering Cancer Center | |
| A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma | NCT04238819 | Relapsed Solid ... Refractory Soli... | Abemaciclib Irinotecan Temozolomide Dinutuximab GM-CSF | - 21 Years | Eli Lilly and Company | |
| Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma | NCT01241162 | Neuroblastoma Ewings Sarcoma Osteogenic Sarc... Rhabdomyosarcom... Synovial Sarcom... | Autologous dend... | 1 Year - 24 Years | University of Louisville | |
| 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor | NCT05069220 | Neuroendocrine ... Neuroblastoma Pheochromocytom... Paraganglioma | 18F-MFBG 68Ga-Dotatate | 1 Year - 80 Years | Peking Union Medical College Hospital | |
| Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma | NCT01404702 | Neuroblastoma | Zoledronic Acid Aldesleukin | 2 Years - 21 Years | University of Alabama at Birmingham |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
